Sign inCreate account

Report workspace tools

NCT00870818TERMINATEDanonymous

An Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Patients With Recent-Onset Type 1 Diabetes Mellitus

Sponsor

Source record

MacroGenics

Phase

Source record

NA

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Type 1 Diabetes Mellitus

Indication / condition

AI-normalized

Type 1 Diabetes Mellitus

Intervention

Source record

Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets

Source & freshness

Source record

NCT ID

NCT00870818

Original source

ClinicalTrials.gov

Source last updated

Aug 09, 2023

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00870818

Title

An Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Patients With Recent-Onset Type 1 Diabetes Mellitus

Sponsor

MacroGenics

Status

TERMINATED

Phase

NA

Condition raw

Type 1 Diabetes Mellitus

Condition normalized

Type 1 Diabetes Mellitus

Modality raw

Type 1 Diabetes Mellitus

Modality normalized

monoclonal antibody

Target raw

Type 1 Diabetes Mellitus

Target normalized

Type 1 Diabetes Mellitus

Interventions

Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets

Public preview

Source record

The study aimed to evaluate the long-term safety and efficacy of Teplizumab (MGA031), a monoclonal antibody, in patients with recent-onset Type 1 Diabetes Mellitus. The trial was sponsored by MacroGenics in collaboration with Eli Lilly and Company. It was terminated due to a business decision after enrolling 219 participants.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Patients With Recent-Onset Type 1 Diabetes Mellitus

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00870818

Status

TERMINATED

Phase

NA

Sponsor

MacroGenics

Executive brief

Investment-Ready Snapshot

The study aimed to evaluate the long-term safety and efficacy of Teplizumab (MGA031), a monoclonal antibody, in patients with recent-onset Type 1 Diabetes Mellitus. The trial was sponsored by MacroGenics in collaboration with Eli Lilly and Company. It was terminated due to a business decision after enrolling 219 participants.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 09, 2023
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00870818

Indication

Type 1 Diabetes Mellitus

Modality

monoclonal antibody

Target

Type 1 Diabetes Mellitus

Intervention

Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.